Raltegravir
Clinical data | |
---|---|
Trade names | Isentress |
Other names | RAL |
AHFS/Drugs.com | Monograph |
MedlinePlus | a608004 |
License data |
|
Pregnancy category |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 60% (FDA) |
Protein binding | 83% |
Metabolism | Liver (UGT1A1) |
Elimination half-life | 9 hours |
Excretion | feces and urine |
Identifiers | |
| |
JSmol) | |
| |
|
Raltegravir, sold under the brand name Isentress, is an
Common side effects include trouble sleeping, feeling tired,
Raltegravir was approved for medical use in the United States in 2007.
Medical uses
Raltegravir was initially approved only for use in individuals whose infection has proven resistant to other
In December 2011, it approval for use in children over the age of two, taken in pill form orally twice a day by prescription with two other antiretroviral medications to form the cocktail (most
Efficacy
In a study of the drug as part of combination therapy, raltegravir exhibited potent and durable antiretroviral activity similar to that of
Side effects
Raltegravir was generally well tolerated when used in combination with optimized background therapy regimens in treatment-experienced patients with HIV-1 infection in trials of up to 48 weeks' duration.[13]
Mechanism of action
As an
Chemistry
Raltegravir has been synthesized in several ways, which have been reviewed.[15][16]
In one method used for its manufacture, 2-amino-2-methylpropanenitrile is reacted with the
History
Raltegravir was the first integrase inhibitor to receive approval in the United States in October 2007.[18][8][19] It was developed by Merck and reported by Summa et al. in the Journal of Medicinal Chemistry.[20]
Research
Raltegravir significantly alters HIV
Research results were published in the
Research on
In January 2013, a Phase II trial was initiated to evaluate the therapeutic benefit of raltegravir in treating multiple sclerosis (MS).[25] The drug is active against Human Endogenous Retroviruses (HERVs) and possibly Epstein–Barr virus, which have been suggested in the pathogenesis of relapsing-remitting MS.[citation needed]
References
- ^ "Product monograph brand safety updates". Health Canada. 7 July 2016. Retrieved 1 April 2024.
- ^ "Isentress 400 mg Film-coated Tablets - Summary of Product Characteristics (SmPC)". (emc). Retrieved 11 July 2021.
- ^ "Isentress- raltegravir tablet, film coated Isentress- raltegravir tablet, chewable Isentress- raltegravir granule, for suspension". DailyMed. Retrieved 11 July 2021.
- ^ "Isentress EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 12 July 2021.
- ^ ISBN 978-0-85711-156-2.
- ^ a b c d e f g "Raltegravir Potassium". The American Society of Health-System Pharmacists. Retrieved 8 December 2017.
- hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
- ^ a b
"Isentress Drug Approval Package". U.S. Food and Drug Administration(FDA). February 22, 2008. Retrieved 2009-11-15.
- ^ "UPDATE 2-FDA OKs widened use of Merck's Isentress HIV drug". Reuters. 2009-07-10.
- ^ "FDA Okays Raltegravir for Kids, Teens with HIV".
- S2CID 6130143.
- PMID 17426263.
- S2CID 195685470.
- ^ "HIV Antiretroviral Agents in Development". www.thebody.com. 30 March 2006.
- ISBN 978-0-470-76859-4.
- S2CID 75449475.
- ^ WO patent 2013098854, Gurjar MK, Sonawane SP, Maikap GS, Patil GD, Shinde SB, Patil PS Mehta SS, "Synthesis of raltegravir", published 2013-07-04, assigned to Emcure Pharmaceuticals Ltd
- ^
"FDA approval of Isentress (raltegravir)". U.S. Food and Drug Administration (FDA). June 25, 2009. Archived from the originalon July 10, 2009. Retrieved 2009-11-15.
- PMID 22035460.
- PMID 18763751.
- ^ "Faster Viral Decay With Raltegravir". www.thebodypro.com. 24 July 2007.
- ^ Clinical trial number NCT00554398 for "Impact of MK-0518 (Raltegravir) Intensification on HIV-1 Viral Latency in Patients With Previous Complete Viral Suppression" at ClinicalTrials.gov
- PMID 18650512.
- ^ "Drug against AIDS could be effective against herpesvirus". ScienceDaily.
- ^ Giovannoni G (24 May 2017). "Raltegravir (Isentress) Pilot Study in Relapsing Multiple Sclerosis - Full Text View - ClinicalTrials.gov". clinicaltrials.gov.
External links
- World patent covering the potassium salt Archived 2007-10-14 at the Wayback Machine